


## **A Market Leading Aquaculture Biotechnology Company**





# **Sea Lice Damage 'Brand Salmon' and Constrain Industry Growth**





Sea lice have become resistant to most current medicines

Some major treatments have welfare issues

Benchmark have introduced the first new sea lice medicine to the Norwegian market in over a decade




## **CleanTreat**®

- An innovative standalone solution that removes the treatment from the water before returning to the sea
- Potential application to all bath treatments
- Also filters out organic matter including sea lice and egg strings, an essential step in combating parasitic resistance to medicine
- Trained technical staff for operating the system and trained analytical staff for performing sample analysis to confirm the purification process
- ASC concluded that any treatments performed in a closed contained system, that then applies water purification steps to remove the veterinary medicine, will receive a score of 'zero' – the best score possible.










Disclaimer: Ectosan® Vet should be used in-line with the product SPC.



## Field Performance of CleanTreat®

Since the launch of Ectosan® Vet on the 11<sup>th</sup> of August 2021, CleanTreat® has purified a significant volume of treatment water whilst working with Norway's largest producers

- Purified water from more than 330 treatments along the Norwegian coast, treating over 130,000 tons of Salmon
- Increased average wellboat transfer rate from 500 to 670m<sup>3</sup>/hr
- Achieved a maximum water transfer rate of 1,190m<sup>3</sup>/hr
- CleanTreat® vessel storage capacity of 2,600/2,800 m³
- Purified over 1,300,000m<sup>3</sup> of spent treatment water



#### **Disclaimer**

#### **Confidentiality**

This document and the information contained within it, is commercially sensitive and therefore strictly confidential. It is intended solely for the purpose of information sharing.

You are hereby notified that any disclosure, copying, distribution or taking action in relation to the contents of this material, without the prior written permission of Benchmark Holdings plc, is strictly prohibited and infringes the intellectual property rights of Benchmark Holdings plc.

#### **Disclaimer**

Benchmark takes no responsibility for any claims that may arise from information contained in this document.

This document contains forward looking statements. These forward-looking statements reflect the knowledge and information available to Benchmark during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty, and it is acknowledged that the circumstances contemplated by these forward looking statements may not be realised. These forward-looking statements speak only as at the date of this presentation, and each of the Company, and its respective agents, employees, advisers or affiliates, expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

Copyright © 2023 Benchmark Holdings plc. This document and the information contain within is the copyright of Benchmark Holdings plc. All rights reserved. Benchmark and associated logos are registered trademarks of Benchmark Holdings plc.

